Payment overview · 2025
General Payments
$111.22
5 reported records · 4 companies
Healthcare provider profile · identity verified
Omar Perez, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL MONTE, CA · NPI 1043393465
Verified facts
What the public records show
CMS Open Payments records show Omar Perez, MD received $111.22 in general payments during 2025 across 5 reported records.
DePuy Synthes Sales Inc. accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $38.37 | 34.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.99 | 30.6% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $24.56 | 22.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.30 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.22 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CEREPAK UNIFORM Normalized: cerepak uniform |
Device | DePuy Synthes Sales Inc. | $38.37 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 484 | 162 |
| Metformin Hcl | Metformin Hcl | 405 | 135 |
| Alendronate Sodium | Alendronate Sodium | 338 | 123 |
| Gabapentin | Gabapentin | 294 | 96 |
| Carvedilol | Carvedilol | 284 | 80 |
| Omeprazole | Omeprazole | 272 | 97 |
| Montelukast Sodium | Montelukast Sodium | 249 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 102 |
| Losartan Potassium | Losartan Potassium | 231 | 79 |
| Ibuprofen | Ibuprofen | 228 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 73 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 170 | 53 |
| Celecoxib | Celecoxib | 158 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 63 |
| Jardiance | Empagliflozin | 154 | 39 |
| Furosemide | Furosemide | 149 | 52 |
| Simvastatin | Simvastatin | 145 | 43 |
| Valsartan | Valsartan | 142 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 140 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 48 |
| Famotidine | Famotidine | 121 | 37 |
| Glimepiride | Glimepiride | 120 | 36 |
| Alprazolam | Alprazolam | 119 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 47 |
| Lisinopril | Lisinopril | 116 | 43 |
| Dutasteride | Dutasteride | 112 | 40 |
| Glipizide | Glipizide | 111 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 31 |
| Azithromycin | Azithromycin | 103 | 62 |
| Januvia | Sitagliptin Phosphate | 99 | 23 |
| Benazepril Hcl | Benazepril Hcl | 97 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 18 |
| Lorazepam | Lorazepam | 86 | 21 |
| Ketoconazole | Ketoconazole | 85 | 30 |
| Spironolactone | Spironolactone | 80 | 29 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 25 |
| Entresto | Sacubitril/Valsartan | 67 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 65 | 17 |
| Naproxen | Naproxen | 65 | 34 |
| Cilostazol | Cilostazol | 64 | 24 |
| Fenofibrate | Fenofibrate | 59 | 23 |
| Farxiga | Dapagliflozin Propanediol | 58 | 14 |
| Myrbetriq | Mirabegron | 57 | 12 |
| Nitroglycerin | Nitroglycerin | 57 | 27 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 55 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 21 |
| Cephalexin | Cephalexin | 52 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 22 |
| Meclizine Hcl | Meclizine Hcl | 50 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 17 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Eliquis | Apixaban | 46 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 40 | 14 |
| Diazepam | Diazepam | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 17 |
| Donepezil Hcl | Donepezil Hcl | 35 | 12 |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Meloxicam | Meloxicam | 35 | 14 |
| Tramadol Hcl | Tramadol Hcl | 35 | 18 |
| Finasteride | Finasteride | 34 | 11 |
| Ozempic | Semaglutide | 33 | suppressed |
| Ranolazine Er | Ranolazine | 33 | 11 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Nateglinide | Nateglinide | 30 | 14 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | 12 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Permethrin | Permethrin | 24 | 13 |
| Saxagliptin Hcl | Saxagliptin Hcl | 24 | suppressed |
| Ursodiol | Ursodiol | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Humalog | Insulin Lispro | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Calcipotriene | Calcipotriene | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Imiquimod | Imiquimod | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.22 · 5 records | DePuy Synthes Sales Inc. | CEREPAK UNIFORM, General - Pain Management, Kerendia, Natroba, Spinosad | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error